Peptide ReadinessJoin the beta
Back to database

FDA APPROVED COMPARATOR

Tirzepatide

A critical UK comparator showing how a multi receptor peptide can progress into mainstream obesity care.

Conceptual three-dimensional molecular signature for Tirzepatide; not an exact chemical structure.
GIP and GLP-1 receptor agonist peptideConceptual molecular signature · not an exact chemical structure
Record version 1.0Last verified 5 September 2026Evidence grade AAuthorised product precedent
FDA STATUS

FDA approved in specific products and indications

MHRA / UK LICENCE

UK authorised in specific products and indications

NICE STATUS

NICE TA1026 recommends tirzepatide with eligibility criteria

NHS ACCESS

NHS access is phased and prioritised under implementation policy

PRIVATE LAWFUL USE CONTEXT

Lawful private prescribing is product, indication and prescriber specific

EVIDENCE MATURITY

Authorised medicine with pivotal obesity and diabetes evidence

DEVELOPMENT PHASE

Authorised product precedent

MARKET EXPOSURE

Very high

PROFESSIONAL RELEVANCE

Track NHS implementation, capacity, access criteria and real world outcomes as a readiness comparator for next generation metabolic peptides.

Product, formulation and indication

Mounjaro

UK · Injection

Type 2 diabetes and weight management

Zepbound

US · Injection

Chronic weight management

Status history

Production baseline verification recorded.

Established FDA approved dual agonist

Future material changes will be appended with their previous status and source; they will not be silently overwritten.

Verify this record

Source labels identify what each link can prove. Sponsor material is used for time sensitive development claims only.